Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive markers of efficacy of cetuximab plus irinotecan in metastatic colorectal cancer
2008-004904-29Phase 2Terminated
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and irinotecan in metastatic colorectal adenocarcinoma (mCRC) and colon cancer, sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoints: Correlation between response and predictive markers and Time to progression. Started Sep 2008; status: terminated.
02
Drugs
cetuximabirinotecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colon cancer
Beyond the preview
Go deeper on 2008-004904-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004904-29.